Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Medical Supplies Industry Analysis

UpdatedApr 05, 2026
DataAggregated Company Financials
Companies42
  • 7D4.1%
  • 3M-0.4%
  • 1Y-2.9%
  • YTDn/a

In the last week, the Medical Supplies industry is up 4.1%, with Medline up 7.1%. The industry has been flat over the past 12 months despite the gain this week. As for the next few years, earnings are expected to grow by 21% per annum.

Industry Valuation and Performance

Has the U.S. Medical Supplies Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 05 Apr 2026US$129.9bUS$67.7bUS$1.7b21.2x75.6x1.9x
Tue, 03 Mar 2026US$139.5bUS$64.6bUS$2.1b22.2x67.3x2.2x
Thu, 29 Jan 2026US$137.0bUS$63.5bUS$1.4b27.1x98x2.2x
Sat, 27 Dec 2025US$134.5bUS$63.5bUS$958.1m26.8x140.4x2.1x
Mon, 24 Nov 2025US$70.7bUS$36.1b-US$272,793,601.0022.1x-259.1x2x
Wed, 22 Oct 2025US$68.4bUS$36.1b-US$1,348,148,630.0022.6x-50.7x1.9x
Fri, 19 Sep 2025US$65.5bUS$36.1b-US$1,395,631,837.0022x-46.9x1.8x
Sun, 17 Aug 2025US$68.1bUS$36.0b-US$1,388,865,468.0023.6x-49x1.9x
Tue, 15 Jul 2025US$77.0bUS$36.0b-US$855,473,301.7226.2x-90x2.1x
Thu, 12 Jun 2025US$75.7bUS$36.0b-US$853,313,682.4327.2x-88.8x2.1x
Sat, 10 May 2025US$75.2bUS$35.9b-US$847,833,534.0028.7x-88.7x2.1x
Mon, 07 Apr 2025US$71.1bUS$35.9b-US$625,773,350.0023.7x-113.7x2x
Wed, 05 Mar 2025US$83.2bUS$35.7b-US$604,963,882.0026.6x-137.5x2.3x
Fri, 31 Jan 2025US$91.3bUS$35.5bUS$707.9m28.2x128.9x2.6x
Sun, 29 Dec 2024US$87.4bUS$35.5bUS$1.2b31.5x75.2x2.5x
Tue, 26 Nov 2024US$94.4bUS$35.4bUS$1.1b38.5x83.6x2.7x
Thu, 24 Oct 2024US$97.2bUS$35.0bUS$1.6b34.7x59.8x2.8x
Sat, 21 Sep 2024US$103.7bUS$35.0bUS$1.6b42.3x63.2x3x
Mon, 19 Aug 2024US$93.3bUS$35.1bUS$1.6b42.6x57.1x2.7x
Wed, 17 Jul 2024US$92.2bUS$34.8bUS$2.1b41.6x43.8x2.7x
Fri, 14 Jun 2024US$92.6bUS$34.8bUS$2.1b41.8x44x2.7x
Sun, 12 May 2024US$92.5bUS$34.5bUS$2.1b41.7x43.1x2.7x
Tue, 09 Apr 2024US$97.0bUS$34.2bUS$2.1b43.1x47x2.8x
Thu, 07 Mar 2024US$83.7bUS$26.0bUS$652.5m40.8x128.2x3.2x
Sat, 03 Feb 2024US$80.7bUS$26.3bUS$362.6m40.6x222.7x3.1x
Mon, 01 Jan 2024US$84.5bUS$26.2bUS$242.3m40.8x349x3.2x
Wed, 29 Nov 2023US$74.6bUS$26.1bUS$223.3m40.7x334.1x2.9x
Fri, 27 Oct 2023US$70.8bUS$26.0b-US$656,738,930.0035.2x-107.8x2.7x
Sun, 24 Sep 2023US$83.4bUS$25.8b-US$702,386,556.0034.3x-118.8x3.2x
Tue, 22 Aug 2023US$93.2bUS$25.7b-US$689,292,515.0033.5x-135.2x3.6x
Thu, 20 Jul 2023US$98.4bUS$25.1b-US$585,997,843.0035.2x-167.9x3.9x
Sat, 17 Jun 2023US$96.0bUS$25.6b-US$571,799,580.0036x-167.9x3.8x
Mon, 15 May 2023US$94.3bUS$25.6b-US$418,264,731.0035.2x-225.5x3.7x
Wed, 12 Apr 2023US$96.6bUS$25.4b-US$331,242,493.0046.7x-291.6x3.8x
Price to Earnings Ratio

-291.6x


Total Market Cap: US$96.6bTotal Earnings: -US$331,242,493.00Total Revenue: US$25.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Medical Supplies Industry Price to Earnings3Y Average 6.5x202420252026
Current Industry PE
  • Investors are optimistic on the American Health Care Supplies industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 75.6x which is higher than its 3-year average PE of 6.5x.
  • The 3-year average PS ratio of 2.7x is higher than the industry's current PS ratio of 1.9x.
Past Earnings Growth
  • Total earnings for the Health Care Supplies industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 39% per year.
  • This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.

Industry Comparison

How does U.S. Medical Supplies compare with similar industries?

US Market3.46%
Healthcare3.50%
Medical Equipment0.0019%
Medical Supplies4.14%
Medical Equipment-0.48%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
MDLN MedlineUS$44.287.1%
+US$2.4b		n/aPE31x
BLCO Bausch + LombUS$16.497.3%
+US$396.8m		36.2%PS1.1x
ALGN Align TechnologyUS$170.602.5%
+US$300.8m		11.1%PE29.6x
NEOG NeogenUS$9.418.2%
+US$154.4m		20.6%PS2.3x
SOLV SolventumUS$63.571.3%
+US$140.5m		-4.0%PE7.1x

Latest News

LNTH
US$76.10
Lantheus Holdings
7D
2.2%
1Y
-16.3%

LNTH: Future Upside Will Depend On Execution In Radiodiagnostic Portfolio

Analysts have lifted the implied fair value for Lantheus Holdings by about $7 to roughly $91 per share, reflecting updated views on PSMA PET market volumes, the PYLARIFY TruVu rollout, and broader radiopharmaceutical product and royalty opportunities. Analyst Commentary Recent Street research on Lantheus Holdings has become more constructive overall, with several firms lifting price targets and a few voices sounding more cautious on execution and portfolio focus.
NSPR
US$1.54
InspireMD
7D
-3.1%
1Y
-41.7%
MMSI
US$67.70
Merit Medical Systems
7D
-1.5%
1Y
-26.8%
MDLN
US$44.28
Medline
7D
7.1%
1Y
n/a

Medline: A Lack Of Compelling Risk-Reward Makes Me Cautious

Apr 03
VNRX
US$0.17
VolitionRx
7D
-12.8%
1Y
-67.8%
XTNT
US$0.49
Xtant Medical Holdings
7D
-11.0%
1Y
4.7%
HAE
US$56.83
Haemonetics
7D
5.2%
1Y
-6.7%
NEOG
US$9.41
Neogen
7D
8.2%
1Y
20.6%

NEOG: Earnings Outlook Will Benefit From Recall Actions And New Guidance

Analysts have raised their price target on Neogen from $8.17 to $11.67 per share, citing updated assumptions related to the discount rate, revenue growth, profit margins, and a higher future P/E multiple. What's in the News Neogen is voluntarily recalling all lots within expiry of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL / 50 mg vials.
BLCO
US$16.49
Bausch + Lomb
7D
7.3%
1Y
36.2%
SOLV
US$63.57
Solventum
7D
1.3%
1Y
-4.0%
ALGN
US$170.60
Align Technology
7D
2.5%
1Y
11.1%
TELA
US$0.60
TELA Bio
7D
-10.9%
1Y
-44.7%
ICUI
US$123.31
ICU Medical
7D
-0.7%
1Y
-11.5%
STAA
US$20.21
STAAR Surgical
7D
13.0%
1Y
26.9%

STAA: Ongoing China Uncertainty And Governance Turmoil Will Pressure Shares

Analysts have reduced the consolidated price target for STAAR Surgical to $22 from $28, reflecting lower assumptions for revenue growth and profit margins, a much higher future P/E multiple, and ongoing uncertainty around China and the company’s broader path forward. Analyst Commentary Recent Street research on STAAR Surgical points to a cautious tone, with multiple bearish analysts cutting price targets and reiterating neutral or underweight stances.
MMED
US$14.01
Minimed Group
7D
-3.2%
1Y
n/a
STSS
US$1.51
Sharps Technology
7D
-4.4%
1Y
-80.5%